Atezolizumab/catequentinib: Asthma.

A 57-year-old woman developed asthma while being treated with atezolizumab and catequentinib for extensive-stage small-cell lung cancer. She had no history of asthma, allergies, or smoking, and no family history of hereditary disease, asthma, or tumors. The woman's tumor size decreased significantly after four cycles of treatment, but she experienced severe dyspnea before the 12th cycle. Tests revealed bronchial mucosal congestion, edema, and secretions, as well as increased IgE levels and eosinophil counts. She was diagnosed with asthma secondary to the treatment and started receiving medication, which improved her symptoms. Her tumor status remained stable, and she had no systemic metastases. [Extracted from the article]